Gates Foundation’s Vir Biotechnology VIR Stock Holding History

Gates Foundation’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$11.7M	Hold	1,559,142	–	–	26.85%	2
2024 Q2	$13.9M	Hold	1,559,142	–	–	34.5%	1
2024 Q1	$15.8M	Hold	1,559,142	–	–	18.77%	2
2023 Q4	$15.7M	Hold	1,559,142	–	–	17.45%	3
2023 Q3	$14.6M	Hold	1,559,142	–	–	17.42%	3
2023 Q2	$38.2M	Hold	1,559,142	–	–	30.44%	1
2023 Q1	$36.3M	Hold	1,559,142	–	–	32.04%	1
2022 Q4	$39.5M	Hold	1,559,142	–	–	30.41%	1
2022 Q3	$30.1M	Hold	1,559,142	–	–	23.79%	1
2022 Q2	$39.7M	Hold	1,559,142	–	–	30.52%	1
2022 Q1	$40.1M	Buy	1,559,142 +881,365	+130%	+$26.1M	21.56%	1
2021 Q4	$28.4M	Hold	677,777	–	–	8.62%	6
2021 Q3	$29.5M	Sell	677,777 -2,100,000	-76%	-$90.9M	8.64%	4
2021 Q2	$131M	Hold	2,777,777	–	–	20.13%	3
2021 Q1	$142M	Hold	2,777,777	–	–	23.3%	2
2020 Q4	$74M	Buy	+2,777,777	New	+$90.3M	16.9%	3

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Gates Foundation's VIR Position: Q3 2024 in Review

Gates Foundation held its Vir Biotechnology (VIR) position steady in Q3 2024 at 1,559,142 shares worth $11.7M. The position accounts for 26.85% of the portfolio, ranked #2.

Gates Foundation first reported a position in VIR in Q4 2020 and has held it in 16 quarters since. The position peaked at $142M in Q1 2021. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

Gates Foundation held 1,559,142 shares of Vir Biotechnology worth $11.7M as of Q3 2024.
Gates Foundation left its Vir Biotechnology share count unchanged in Q3 2024.
Vir Biotechnology made up 26.85% of Gates Foundation's portfolio in Q3 2024, its #2 holding.
Gates Foundation first reported a position in Vir Biotechnology in Q4 2020 and has held it in 16 quarters since.
Gates Foundation's Vir Biotechnology position peaked at $142M in Q1 2021.
197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Gates Foundation's 13F filing for Q3 2024, filed 14 Nov 2024.